Jung Sang Hun, Kim So Hyun, Kim Jae Hwang
Department of Surgery, Yeungnam University College of Medicine, Daegu, Korea.
Ann Coloproctol. 2016 Apr;32(2):58-65. doi: 10.3393/ac.2016.32.2.58. Epub 2016 Apr 30.
Mucinous cells (MUCs), signet-ring cells (SRCs), and poorly differentiated cells (PDCs) are uncommon histologic types and have been associated with advanced tumor stage and poor prognosis. However, MUCs, SRCs, and PDCs are commonly observed in cancers with high microsatellite instability (MSI), which have favorable outcomes compared with cancers with microsatellite stability (MSS). The purpose of this study was to evaluate the prognostic impact of high-MSI in patients with sporadic colorectal cancer presenting with MUCs, SRCs, and/or PDCs.
Between January 2006 and December 2012, 176 with proven microsatellite status who also presented with MUCs, SRCs, and PDCs were selected for this study and were divided into 2 groups, high-MSI and MSS; their outcomes were analyzed.
Of the 176 patients, 56 and 120, respectively, had high-MSI and MSS cancers. High-MSI cancers had larger tumors, proximal tumor location, and a lower TNM stage. The recurrence rate was lower in the high-MSI group (13.7% vs. 35.4%, P = 0.006). Common patterns of distant metastasis for MUC, SRC, PDC cancers were peritoneal spread (46.9%) and hematogenous metastasis (46.4%). The 5-year CSS rates were 88.2% and 61.2% for patients with high-MSI and MSS cancers, respectively (P < 0.0001). In the multivariate analysis, except for stage-IV cancer, MSI status was an independent risk factor for cancer-specific survival (MSS: hazard ratio, 4.34; 95% confidence interval, 1.68-11.21).
In patients with colorectal cancer presenting with MUCs, SRCs, and/or PDCs, those with high-MSI cancers had better outcomes.
黏液细胞(MUCs)、印戒细胞(SRCs)和低分化细胞(PDCs)是不常见的组织学类型,与肿瘤晚期及预后不良相关。然而,MUCs、SRCs和PDCs常见于微卫星高度不稳定(MSI)的癌症中,与微卫星稳定(MSS)的癌症相比,其预后较好。本研究旨在评估MSI高表达对散发性结直肠癌伴MUCs、SRCs和/或PDCs患者预后的影响。
选取2006年1月至2012年12月间176例经证实微卫星状态且伴有MUCs、SRCs和PDCs的患者进行研究,分为两组,即MSI高表达组和MSS组,分析其预后情况。
176例患者中,分别有56例和120例为MSI高表达和MSS癌症。MSI高表达的癌症肿瘤更大,位于近端,TNM分期更低。MSI高表达组的复发率更低(13.7%对35.4%,P = 0.006)。MUC、SRC、PDC癌症常见的远处转移模式为腹膜播散(46.9%)和血行转移(46.4%)。MSI高表达和MSS癌症患者的5年无病生存率分别为88.2%和61.2%(P < 0.0001)。多因素分析中,除IV期癌症外,MSI状态是癌症特异性生存的独立危险因素(MSS:风险比,4.34;95%置信区间,1.68 - 11.21)。
对于伴有MUCs、SRCs和/或PDCs的结直肠癌患者,MSI高表达的患者预后更好。